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Abstract
The present study was conducted to investigate the usefulness of the direct leucocyte migration
agarose method for studying cell-mediated immunity in vitro. Comparative studies of the purified
protein derivative (PPD) skin test and the leucocyte migration inhibition test (LMIT) in which
PPD was used as test antigen indicated a significant qualitative and a weak quantitative correlation
between these two tests. Furthermore a positive correlation was found between the LMIT and the
macrophage migration inhibition test (MIT) using ultrasonicated authochthonous tumor antigen.
Comparative studies of the LMIT, MIT, PPD skin and DNCB tests on the same patients showed
that cases responding positively to the the PPD skin and DNCB tests tended to respond positively
to the LMIT and MIT. Patients with digestive organ cancers were examined by the LMIT. With the
advance of cancer, decreased positive test test rates were found. After gastric cancer operations
the LMIT findings were divided into two groups: one type changed from positive to negative,
and the other type changed from negative to positive. The former response was suggestive of
a successful operation, and the latter response was suggestive of a non-curative operation. These
results indicated that the direct leucocyte migration inhibition agarose test was useful investigating
cell-mediated immunity.
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Abstract. The present study was conducted to investigate the
usefulness of the direct leucocyte migration agarose method for study-
ing cell-mediated immunity in vitro. Comparative studies of the puri-
fied protein derivative (PPD) skin test and the leucocyte migration
inhibition test (LMIT) in which PPD was used as test antigen indicated
a significant qualitative and a weak quantitative correlation between
these two tests. Furthermore, a positive correlation was found between
the LMIT and the macrophage migration inhibition test (MIT) using
ultrasonicated autochthonous tumor antigen. Comparative studies of
the LMIT, MIT, PPD skin and DNCB tests on the same patients
showed that cases responding positively to the PPD skin and DNCB
tests tended to respond positively to the LMIT and MIT. Patients
with digestive organ cancers were examined by the LMIT. With the
advance of cancer, decreased positive test rates were found. After
gastric cancer operations the LMIT findings were divided into two
groups: one type changed from positive to negative, and the other
type changed from negative to positive. The former response was
suggestive of a successful operation, and the latter response was sug-
gestive of a non-curative operation. These results indicated that the
direct leucocyte migration inhibition agarose test was useful for inves-
tigating cell-mediated immunity.
Experimental tumor transplantation studies have shown that tumor-bearing
animals possess cell-mediated immunity against tumor cells. In man such in vivo
methods are not possible and it is necessary to develop various in vitro parameters
for evaluating cell-mediated immunity. Both specific and non-specific tests are
necessary to meet such requiremen,ts. Specific tests include the lymphocyte direct
cytotoxicity test, tumor colony inhibition test, estimation of lymphokine, espe-
cially the macrophage migration inhibitory factor (MIF) and the leucocyte mi-
gration inhibitory factor (LIF), and mixed lymphocyte-tumor reaction. Non-
specific tests include the estimation of the lymphocyte transformation rate against
mitogens, peripheral lymphocyte counts, and the ratio between B-cells and T-
cells (l). It is usually not easy to obtain target tumor cell strains by tissue culture
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and thus a cytotoxicity test can not normally be conducted. Therefore clinically
cell-mediated immunity is being investigated by the macrophage migration in-
hibition test (MIT) and the lymphocyte transformation rate against mitogens.
It is well known that when sensitized T-cells are in contact with respective
antigens, cell-free mediators (so-called lymphokines) are liberated (2). The most
commonly known lymphokine at present is MIF. It was reported that MIF
activity had a close mutual relationship with the delayed-type of hypersensitivity
(3). Akiyama (4) obtained favorable results in diagnosing malignant tumors by
MIT. However, it is not possible to measure the total immunological potential
by MIT, so that other parameters are required to determine this capacity more
precisely. The present study was conducted to determine whether the leucocyte
migration inhibition test (LMIT) can serve as a parameter for cell-mediated im-
munity.
S¢borg and Bendixen (5) measured LIF activity by the capillary tube method
and reported it to be an excellent method for studying cell-mediated immunity.
Since then, many confirmatory studies have appeared using various antigens
(6-9). This method, however, requires a large quantity of blood so that it is
difficult to use as a routine test.
In 1971 Clausen (10) developed a leucocyte migration agarose test that was
simple to manipulate and was highly reproducible with a small quantity of blood.
Some reported (11-13) the usefulness of the agarose test with soluble antigen and
tumor extract antigen.
In the present investigation LMIT and MIT were carried out simultaneously
with patient peripheral blood to study the relationship between the two tests and
the relationship between LMIT and the macroscopic stage of gastric cancer and
colon cancer. Postoperative immunity was followed-up in some gastric cancer
patients. Furthermore, comparisons were made between LMIT and MIT and
between the purified protein derivative (PPD) and 2,4- dinitrochlorobenzene
(DNCB).
MA TERIALS AND METHODS
Subjects. The subjects of the study consisted of 58 cases of gastric cancer
and 20 cases of colon cancer, operated in the First Department of Surgery, Oka-
yama University Medical School. The gastric or colon cancer stages were clas-
sified in accordance with the recommendations of the Japanese Gastric Cancer
Research Society (14). The gastric cancer patients were classified as follows:
9 cases in stage I to II, 16 cases in stage III and 15 cases in stage IV. The colon
cancer patients were classified into 10 cases in stage I to II and 10 cases in stage
III to IV.
Skin test. PPD skin and DNCB tests were conducted. PPD (Japan BCG
Co.) was injected intradermally at 0.05pg/O.lml at the middle of the flexion side
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of the forearm, and the reaction was measured 48 hr later. When the redden
diameter area was less than 5 mm, the reaction was judged negative, and diam-
eters over 10 mm were considered positive. For the DNCB test 0.05ml of 2%
acetone solution of DNCB (DNCB, Wako Co.) was smeared over a 2cm skin
area of the inner thigh, and the flare-up reaction was measured 14 days later.
If there was no reaction, 0.05ml of 0.1 % DNCB solution was again smeared, and
the final determination was made 48 hr later by the reddenin~ and induration
response.
Preparation of lymphocytes. Lymphocytes were isolated according to the
method of Boyum (15). Two to three ml of heparinized peripheral blood were
mixed with 6ml of 0.9% physiological saline solution. The diluted blood (6-9 ml)
was poured gently over a layer of 3 ml Ficoll-Conray mixture solution in a test
tube. The tube was centrifuged at 2,000 rpm for 30 min, and the lymphocyte
layer was aspirated. This lymphocyte layer was mixed with 0.9% saline and
centrifuged at 2,000 rpm for 10 min. The cells were washed with 0.9% saline
three times, and the lymphocytes were suspended in TC-199.
Preparation of macrophages. Fluid paraffin (20-30 ml) was injected into the
peritoneal cavity of a guinea pig, and 4-5 days later the animal was sacrificed
by bleeding after severing the cervical artery under ether anesthesia. The ab-
dominal wall was opened, the cavity was rinsed with 100-150 ml saline solution
and the rinsed fluid was collected. The fluid was centrifuged at 1,000 rpm for
5 min. The precipitated cells were washed three times and suspended in TC-
199.
Preparation of antigens for LMIT and MIT. PPD was used as antigen at a
concentration of 100pg/ml. Tumor antigen was prepared as follows. About
one gram of tumor harvested aseptically at operation was minced and sonicated
at 20 Kc for 15 min (71' tip, 150 rnA) in about 5 ml of TC-199. The homogenate
prepared was centrifuged at O°C at 3,000 rpm for 30 min, and the supernatant
was used as tumor antigen. Protein concentration was determined by Lowry's
method (16). Non-specific migration inhibtiton to normal human leucocytes was
measured by LMIT using the agarose method. The percent migration± S. D.
was: 92.0 ± 7.0 at 50pg of antigen/ml; 92.3± 3.3 at 100pgiml; 87.0 J-1.2 at 200pg/ml;
84.3±4.1 at 400pg/ml; and 73.3±10.8 at 800pg/ml (Fig. 1). Antigen at 4OOpg/ml
was used as the optimal concentration. The optimal concentration of antigen
solution for MIT was set at 5O-l001tg of proteinml of TC-199. This concentra-
tion was determined previously by preliminary testing.
Macrophage migration inhibition test (direct method). This test was carried out
according to the method of George and Vaughan (17). Peritoneal exudative
cells and lymphocytes were mixed in a ratio of 4: 1; the mixture was sealed in
a capillary tube (micropipet 75 mmx 1.5mm, Terumo Co., Tokyo), and cells
were precipitated to the bottom of the micropipet by centrifugation at 800 rpm
for 3 min. After cutting the micropipet at 1-2 mm distance from the end of the
precipitated cell layer, the capillary was fixed on the bottom of a Mackaness
type micro-Petri dish. The capillary specimens were divided into two groups.
To one group was added TC-199 containing antigen and 20% bovine serum, and
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to the other group was added TC-199 containing 20% bovine serum as a control.
The micro-Petri dish was sealed with a cover glass, incubated at 37°G for 24 hr
in a 5% CO2-incubator, and the migration area was measured. Four capillaries
were used in one group to measure the average migration area, and the migra-
tion index was calculated by the following formula:
~acr.oph.age = AV~~(i!f~ ~~gration area of antigen-added group X 100 %
mlgra tlOn mdex Average migration area of antigen-free control group ()
~
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Fig. 1. Optimal concentration of tumor antigen IMean±S. D.).
Preparation of agarose plate. A 2% solution of Bacto-agar (Difco, U. S. A.)
was prepared with sterile water and autoclaved. When the solution cooled to
47°C, TC-199 (10 time strength), horse serum, NaHC03 and sterile water were
added to make a final concentration of 1% Bacto-agar, 10% horse serum, 400,ug
NaHC03/ml and single strength TC-199. The final pH of the solution was 7.3.
Six ml of the 1% solution of Bacto-agar were poured into a disposable plastic
Petri dish (SOx 15 mm, Wako Pure Chemicals), and allowed to harden. The
dish was then placed in a refrigerator for 30 min to sufficiently harden the agar
in the agar wells. Six holes 3 mm in diameter were made in the agar plate with
a stainless steel punch, and the agar plugs were plucked out by a hypodermic
needle.
Preparation of leucocytes. Ten ml of heparinized peripheral blood were
poured into a test tube and left standing at 37°C for one hour to allow the red
cells to sediment. The buffy coat layer was collected and was centrifuged at
1,000 rpm for 5 min. The precipitated leucocytes were washed three times with
physiological saline solution. When the erythrocyte contamination was marked,
the red cells were disrupted by treatment with hypotonic saline solution (0.35%).
The viability ofleucocytes after the treatment was over 97% by the trypan-blue
exclusion test. Leucocytes were suspended in TC-199. The composition of cells
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in the buffy coat was 60~94% (68% average) polymorphonuclear cells and 6-40%
(32% average) mononuclear cells. Leucocytes at 2x 107 were usually obtained
from 10 ml of peripheral blood.
Direct leucocyte migration inhibition test (agarose method). Leucocytes pre-
pared as described above were divided equally into two test tubes. Tumor an-
tigen was added in one tube, and another tube was used as the control. The
cell number in each test tube was adjusted to 2x 108/ml. Both tub~s were pre-
incubated at 37°C for 30 min, and then 10Itl of cell suspension (2x 106 cells) was
distributed into each well by a microsyringe (Hamilton Co.). Each specimen was
tested independently three times. After incubating the agar plate in the 5% COz-
incubator at 37°C for 18 hr, the plate was fixed with ethanol-formalin solution,
and removed from the Petri dish. The plate was stained with May-Grunwald-
Giemsa solution. The mean diameter (2 r) of the migration area was measured
by a micrometer (Mini Master, Tajima Industry Co.) and the migration area
was calculated as: ;r r Z minus the area of well.
Leucoc te migration index = Ave~Gl.~~rn_~grat~on area of ant.igen-added ~roup.X 100 (%)
y Average mIgratIOn area of antigen-free group
For determination of significant differences, the Student's t-test or Chi-
square test was used.
RESULTS
PPD skin test and L1F activity. Both the PPD skin test and the LMIT using
100pg/ml of PPD antigen were conducted on the same 20 patients (Fig. 2).
There was a highly significant difference between the LIF positive-skin test posi-
tive group and the LIF negative-skin test negative group (P<O.OI). The correla-
tion between the degree of the LIF activity inhibition and the strength of the skin
test was - 0.52.
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Fig. 2. Correlation of leucocyte migration index and
the PPD skin test. 0, skin test negative; e, skin test
positive.
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Comparison of LIF and MIF activity in gastric cancer patients and colon cancer
patients. LMIT and MIT were simultaneously conducted 90 times in 47 gastric
cancer patients and 20 times in 16 colon cancer patients to determine the correla-
tion between these two activities (Fig. 3). The index r was found to be .62 in
gastric cancer cases and .70 in colon cancer cases.
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Fig. 3. Correlation of LIF activity and MIF activity on patients with
gastric cancer and colon cancer.
LIF activity in various stages of gastric and colon cancer. In gastric cancer, the
LIF positive rates were (Fig. 4): stage I plus stage II, 44.4 % (4 of 9 cases); stage
III, 37.5% (6 of 16 cases); and stage IV, 13.3% (2 of 15 cases). Although these
differences were not statistically significant, a trend was apparent for more ad-
vanced patients to show negative LIF activity. In colon cancer, the LIF positive
rates were: stage I plus stage II, 7 of 10 cases and stage III plus stage IV, 3 of 10
Gastric cancer Colon cancer
100 ~ 100
: I
50 50
J + II I m I IV I f+I1 I III + IV I
Stage Stage
44.4 '/c 37.5°/c 13.3'1, 70 % 30 :-/c
Positive Positive
Fig. 4. LIF activity of patients with gastric cancer and
colon cancer.
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cases. This difference was not statistically significant but the same trend toward
negative LIF was present with an advance in cancer.
Correlation between PPD skin test and DNCB test. Both the PPD skin test and
DNCB test were conducted on 46 cancer patients. A significant difference was
not present in the responses to these tests (Table 1).
TABLE 1. RELATIONSHIP BETWEEN PPD SKIN TEST AND DNCB TEST
PPD skin test
DNCB test
Negative
Positive
Total
Negative
5
7
12
Positive
9
25
34
Total
14
32
46
Correlation between LIF activity, MIF activity and DNCB test. No case re-
sponded positively to LMIT when responding negatively to the DNCB test (0 of
6 cases), but 55.5 % of cases (6 of 11 cases) responded positive to both the DNCB
test and LMIT (Fig. 5). A significant difference (p<0.05) was present between
X
Ql
~
§ 100
~
Cl
"E
$
~
o 50g
Ql
....I
ONCS reaction
Negative
ONCS reaction
Fig. 5. Relationship between DNCB test versus
LIF activity and MIF activity.
the DNCB positive-LIF positive group and the DNCB negative-LIF posItlve
group. In cases negative to the DNCB test, the MIF activity was not positive
(0 of 5 cases), and in those positive to the DNCB test, the MIF positive rate was
70% (7 of 10 cases). This difference between the DNCB positive-MIF positive
group and DNCB negative-MIF positive group was statistically significant (p<
0.05).
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Correlation between LfF activity, MfF activity and PPD skin test. In patients
negative to the PPD skin test, no case showed positive LIF activity (0 of 5 cases),
and in those positive to the PPD skin test, the positive rate of LIF activity was
46% (6 of 13 cases) (Fig. 6). This difference between the PPD positive-LIF
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Fig. 6. Relationship between PPD skin test versus
LIF activity and MIF activity.
positive group and the PPD negative-LIF positive group was not significant. On
the other hand, 1 of 5 cases showed positive MIF activity and negative PPD skin
test. The MIF positive rate in those positive on the PPD skin test was 54 % (7 of
13 cases). This difference between the PPD positive-MIF positive group and the
PPD negative-MIF positive group was not significant.
Changes in LfF activity before and after operation in gastric cancer patients. In
11 gastric cancer patients (stage III and IV), LIF activity was measured before
and after the operation (Fig. 7). There were three cases of positive activity
,....
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0 100~
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Fig. 7. Follow-up of LIF activity in gastric cancer patients.
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before the operation that turned negative after the operation, and all three had
successful operations. On the other hand, there were eight surgery cases that
turned from negative to positive or pseudopositive or that showed no changes,
and five of them had severe metastasis.
DISCUSSION
LMIT was first described by Sq)borg and Bendixen (5) in 1967, though the
assay procedure was not appropriate for routine examination. Federlin et at. (18)
developed a micro-capillary method, and Carpenter et at. (19) and Clausen (10)
developed an agarose plate test. The presence or absence of inhibition of LIF
activity correlated very well with the PPO skin test, but the degree of LIF activity
inhibition did not correlated so well with the strength of the skin test. Clausen
(20) and Astor et at. (11) stated that with the PPO as well as streptokinase-
streptodornase and candida, the skin test results correlated not so quantitatively
as qualitatively with the LMIT results.
Rich and Lewis (21) discovered that cell migration from tissue specimens of
spleen and lymph-node of guinea pig sensitized with BCG was inhibited in the
presence of tuberculin. George and Vaughan (17) observed that the migration of
peritoneal cells prepared from BCG sensitized guinea pig and packed in a capil-
lary tube was inhibited with PPO. Thor et at. (22) and Rocklin et at. (23) found
that MIF liberated from human lymphocytes also inhibited the migration of
heterogenous guinea-pig macrophages. We now have a well-established method
for measuring MIF activity. It was reported that MIT was usefulfor specific
assay of tumor immunity in animals (24-26). Moreover, Akiyama (4) reported
that MIT was useful for diagnosis and prognosis of malignant tumor. We
studied the correlation between LIF and MIF activity in cancer patients to deter-
mine whether LMIT could be used to investigate tumor immunity. A positive
correlation was shown between LIF activity and MIF activity in patients with
gastric cancer or colon cancer, with few exceptions. LMIT was thus thought to
closely reflect tumor immunity. Rocklin (27) reported that LIF had a molecular
weight of 69,000, and that it was non-dialyzable, heat stable at 56°C for 30 min
and inhibited the migration of human and guinea-pig polymorphonuclear leuco-
cytes, but that it did not inhibit the migration of human monocytes and guinea-
pig macrophages. It differed from MIF which has a molecular weight of 35,000
to 55,000, and MIF inhibited the migration of human monocytes and guinea-pig
macrophages (28). It remains unclear whether LIF and MIF are identical bio-
chemically, though clinically both apparently show the same biologic function.
We observed that the positive rate of LIF activity decreased along with the
advance of cancer. The LIF activity was reported to decrease with the advance
in stage in malignant melanoma (29), mammary cancer (30, 31) and colon cancer
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(32). In gastric cancer there has been no report on LMIT, but studies on MIT
have been made by Orita et al. (33, 34), and it was reported that MIF activity
decreased along with the progress of cancer.
We observed some cases showing enhanced migration. Weisbart et al. (35)
reported a new lymphokine in p-fraction, migration enhancement factor, which
accelerated the migration of leucocytes. The precise prope;ties of such lympho-
kine require further studies in the future. Wolberg (36) suggested that the non-
specific toxicity of the tumor extracts might playa role in the inhibition of leuco-
cyte migration. However, we could not find non-specific cytotoxicity against
normalleucocytes at a concentration of 400,ug of protein/m!. A useful antigen
was prepared containing specific tumor antigen by the ultrasonication method.
However, methods for extracting tumor specific transplantation antigen are not
yet perfected, and further improvements are required.
PPD skin test and DNCB test gave low responses as the cancer advanced.
Hughes and Mackay (37) reported with PPD skin tests that the positive rate was
52 %in cancer patients and 81 % in control patients. On the other hand, Waldorf
et at. (38) stated that the PPD skin test in aged person was 58% positive. Thus,
in judging the test values it is necessary to take into consideration the patient's
age. DNCB does not exist in nature so that there is no danger of natural sensi-
tization. Eilber and Morton (39) stated that 93% (27 of 29 cases) of cancer
patients who failed to react to DNCB were inoperable or developed early recur-
rence, whereas 92 % (50 of 54 cases) of patients who reacted to DNCB were free
of disease for 6 months.
Positive correlations were found between LIF activity, MIF activity and
DNCB test. In DNCB positive cases LIF and MIF activities were significantly
positive. In positive PPD skin test cases, the LIF and MIF activities tended to
be positive. These results suggest indirectly that the LIF and MIF activities
decreased with the advance of cancer. The skin test with tumor extract antigen
has not been used in Japan, but in other countries it was reported that about 30%
of patients with solid cancers showed positive responses, and the results coincided
roughly with the cinical findings (40-42). This method has a promising future
as a research tool for measuring specific cell-mediated immunity in vivo.
We could roughly divide gastric cancer patients before and after surgery into
two groups by LIF activity: one group changed from positive to negative and the
other group changed from negative to positive. Patients in the former group
showed favorable response to surgery, and most patients in the latter group were
not improved by surgery. Akiyama (4) reported similar results with various
cancer patients. Patients turning from positive to negative after the operation
had successful operations, but patients turning from negative to positive did not
have successful operations. Other investigators stated that patients with positive
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LIF activity turning negative after the operation had successful operations for
colon cancer (43) and for breast cancer (44). We are now continuing to collect
more data on additional subjects and these further results will be reported in the
future.
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